Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Neurology | Research | Geriatrics | News

Back to Health News

Discovery May Improve Diagnosis of Alzheimer’s, Parkinson’s

Last Updated: August 29, 2012.

 

Markers in cerebrospinal fluid might help distinguish different forms of neurological disease, study finds

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Markers in cerebrospinal fluid might help distinguish different forms of neurological disease, study finds.

WEDNESDAY, Aug. 29 (HealthDay News) -- Four indicators, or "biomarkers," found in cerebrospinal fluid can help differentiate patients with Alzheimer's disease from those with other forms of dementia, and a different biomarker can distinguish patients with Parkinson's disease from those with parkinsonian disorders, researchers say.

Overlapping symptoms, especially in the early stages, can make it difficult to distinguish between regular Parkinson's disease and atypical Parkinsonism, and also between Alzheimer's disease and other forms of dementia, the study authors explained.

The investigators identified the five biomarkers by analyzing cerebrospinal fluid samples from 453 patients with Parkinson's, Parkinson's disease with dementia, Alzheimer's and other forms of dementia.

"Together with earlier published data, our results indicate that these five [cerebrospinal fluid] biomarkers might have clinical value in the differential diagnosis of dementia and/or parkinsonism," concluded Dr. Sara Hall, of Skane University Hospital in Sweden, and colleagues.

The study was published online Aug. 27 in the journal Archives of Neurology.

The findings represent "a significant step forward, demonstrating how a relatively modest panel of robust [cerebrospinal fluid] protein biomarkers can categorize dementias and parkinsonian syndromes on the basis of pathology rather than clinical/behavioral changes," Dr. Richard Perrin, of the Washington University School of Medicine in St. Louis, wrote in an accompanying editorial.

The use of these indicators in cerebrospinal fluid could improve the efficiency of clinical trials and speed up the development and evaluation of new treatments for neurological diseases, Perrin concluded.

More information

The National Parkinson Foundation has more about atypical Parkinsonism.

SOURCE: Archives of Neurology, news release, Aug. 27, 2012

Copyright © 2012 HealthDay. All rights reserved.


Previous: West Nile Cases Still Rising, 66 Dead: CDC Next: Mental Skills Decline More Sharply for Women With Alzheimer's: Study

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.